• Home  
  • Flagship, Roche, Isomorphic, Stellas: Readout Newsletter
Flagship, Roche, Isomorphic, Stellas: Readout Newsletter
- Health

Flagship, Roche, Isomorphic, Stellas: Readout Newsletter

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a lot of news to get into today, including some big developments in oncology.

The need-to-know this morning

Sellas’ blood cancer immunotherapy cut risk of death

An experimental drug from Sellas Life Sciences reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia, the company said this morning.

STAT+ Exclusive Story





This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Source: www.statnews.com

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.